摘要
目的研究丹参酮ⅡA磺酸钠联合西洛他唑治疗腔隙性脑梗死患者的疗效。方法选取2017年4月至2019年1月本院收治的腔隙性脑梗死患者80例作为研究对象,简单随机化分为对照组(40例)、观察组(40例)。两组均给予基础治疗,对照组采取西洛他唑治疗,观察组采取丹参酮ⅡA磺酸钠+西洛他唑治疗。比较两组治疗效果、治疗前后血液流变学[全血粘度、血细胞比容(HCT)、纤维蛋白原(FIB)、红细胞聚集指数(EAI)]、脑血管功能(血液流入时间、脑血流量)、神经功能缺损(NIHSS)评分及生活质量(SF-36)评分及不良反应发生情况。结果与对照组总有效率相比,观察组较高(95.00%比77.50%,P<0.05);观察组治疗4周后全血粘度为(4.57±0.30)mPa/s、HCT为(37.81±2.97)%、FIB为(3.48±0.74)%、EAI为(1.28±0.26)%,均低于对照组(均P<0.05);治疗4周后,观察组血液流入时间较对照组短[(0.21±0.05)s比(0.24±0.06)s],脑血流量较对照组高[(561.14±28.49)ml/min比(528.73±26.44)ml/min],两组比较差异有统计学意义(P<0.05);治疗4周后,观察组NIHSS评分较对照组低[(7.86±1.03)分比(9.01±1.14)分],SF-36评分较对照组高[(75.29±6.09)分比(68.07±5.72)分],两组比较差异有统计学意义(P<0.05);两组均无明显不良反应。结论腔隙性脑梗死患者应用丹参酮ⅡA磺酸钠联合西洛他唑治疗疗效显著,可明显改善血液流变学及脑血管功能,还可促进神经功能恢复,提高生活质量,且无明显不良反应,值得临床推广。
Objective To study the efficacy of sodium tanshinone ⅡA sulfonate combined with cilostazol in the treatment of patients with lacunar infarction.Methods Eighty patients with lacunar infarction admitted to our hospital were enrolled in the study from April 2017 to January 2019.The patients were randomly divided into the control group(40 cases)and the observation group(40 cases).The two groups were given basic treatment,the control group was treated with cilostazol,and the observation group was treated with sodium tanshinone ⅡA sulfonate+cilostazol.The treatment effect,blood rheology[whole blood viscosity,hematocrit(HCT),fibrinogen(FIB),erythrocyte aggregation index(EAI)]before and after treatment,cerebrovascular function(blood inflow time,cerebral blood flow),neurological deficit(NIHSS)score,quality of life(SF-36)score,and adverse reactions were compared between the two groups.Results The total effective rate in the observation group was higher than that in the control group[95.00%(38/40)vs.77.50%(31/40)](P<0.05).After 4 weeks of treatment,the whole blood viscosity in the observation group was(4.57±0.30)mPa/s,HCT was(37.81±2.97)%,FIB was(3.48±0.74)%,EAI was(1.28±0.26)%,which were all lower than those in the control group(P<0.05);the blood inflow time in the observation group was shorter than that in the control group[(0.21±0.05)s vs.(0.24±0.06)s],the cerebral blood flow in the observation group was higher than that in the control group[(561.14±28.49)ml/min vs.(528.73±26.44)ml/min](P<0.05);the NIHSS score in the observation group was lower than that in the control group[(7.86±1.03)vs.(9.01±1.14)],the score of SF-36 in the observation group was higher than that in the control group[(75.29±6.09)vs.(68.07±5.72)](P<0.05).There were no obvious adverse reactions in the two groups.Conclusion Sodium tanshinone ⅡA sulfonate combined with cilostazol has significant curative effect in patients with lacunar infarction,which can improve blood rheology and cerebrovascular function,promote neurological recovery,i
出处
《国际医药卫生导报》
2019年第20期3449-3452,共4页
International Medicine and Health Guidance News
